1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 29,400 | 30,000 | 07.02. | |
| 29,200 | 30,000 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 3 | GlobeNewswire (USA) | ||
| Fr | Spyre Therapeutics appoints Kate Tansey Chevlen as Chief Commercial Officer | 2 | PMLiVE | ||
| 23.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 15.01. | Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating | 1 | Insider Monkey | ||
| 12.01. | Spyre Therapeutics accelerates clinical trial timeline for IBD treatments | 2 | Investing.com | ||
| 12.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 | 174 | GlobeNewswire (Europe) | "6 in '26" expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete... ► Artikel lesen | |
| 12.01. | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| SPYRE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.01. | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 01.01. | Spyre Therapeutics: Biotech-Aktie mit Potenzial | 784 | sharedeals.de | Die Biotechnologiebranche ist geprägt von einem Spannungsfeld zwischen wissenschaftlicher Innovationskraft und der oft fragilen finanziellen Lage vieler Unternehmen. Umso bemerkenswerter sind Fälle... ► Artikel lesen | |
| 17.12.25 | Mizuho initiates Spyre Therapeutics stock with Outperform rating | 5 | Investing.com | ||
| 17.12.25 | Spyre Therapeutics: Mizuho startet Coverage mit "Outperform" und sieht 60 % Potenzial | 3 | Investing.com Deutsch | ||
| 05.12.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 3 | GlobeNewswire (USA) | ||
| 01.12.25 | Spyre stock rating upgraded to Buy at Jones Trading on TL1A blockade potential | 3 | Investing.com | ||
| 07.11.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Grants of Inducement Awards | 1 | GlobeNewswire (USA) | ||
| 04.11.25 | Spyre Therapeutics GAAP EPS of -$0.15 beats by $0.61 | 6 | Seeking Alpha | ||
| 04.11.25 | Spyre Therapeutics reports positive interim data for IBD drug SPY003 | 2 | Investing.com | ||
| 04.11.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody | 81 | GlobeNewswire (Europe) | SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (a4ß7 +... ► Artikel lesen | |
| 04.11.25 | Spyre Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11.25 | Spyre Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.25 | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 26,000 | -3,70 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 65,00 | -7,14 % | Palvella Therapeutics: Clear Street bestätigt Kaufempfehlung im Vorfeld von Studiendaten | ||
| DIANTHUS THERAPEUTICS | 40,800 | -5,12 % | Dianthus Therapeutics, Inc.: Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) | LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress... ► Artikel lesen | |
| LENZ THERAPEUTICS | 14,240 | +1,93 % | LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| AGOMAB THERAPEUTICS | 14,650 | 0,00 % | AgomAb Therapeutics N.V.: Agomab Announces Pricing of Initial Public Offering | ANTWERP, Belgium, February 5, 2026 (GLOBE NEWSWIRE) - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab"), a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen |
Das Unternehmen SPYRE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -2,400 (-8,05 %) liegt der Kurs bei 27,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPYRE THERAPEUTICS INC finden Sie auf Wallstreet Online.